TAK-778
Names
[ CAS No. ]:
180185-61-9
[ Name ]:
TAK-778
Biological Activity
[Description]:
TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.
[Related Catalog]:
[In Vitro]
TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.Continuous treatment with TAK-778 (10 μM) for 1 to 21 days results in an increase in the area of mineralized nodules. TAK-778 at concentrations of 1 μM and higher significantly stimulates the activity of cellular Alkaline phosphatase (ALP). TAK-778 increases slightly but significantly the DNA content of the cells at the confluence stage. Treatment with TAK-778 also results in dose-dependent increases in the amount of soluble collagen and osteocalcin secreted into culture medium from days 5 to 7. TAK-778 enhances the secretion of both TGF-β and IGF-I at every time point during the 21 days of culture. Treatment of the cells with TAK-778 does not induce ALP activity, but does result in a dose-dependent increase in the saturated cell density. TAK-778 at a concentration of 10 μM significantly reduces the saturated cell density[2].
[In Vivo]
Treatment with a single local application of TAK-778/PLGA-MC (0.2 to 5 mg/site) results in a dose-dependent increase in the radio-opaque area formed in the defect. Histological studies show the defect area is occupied by a bony bridge and the newly-formed radio-opaque area corresponds to a calcified bone containing bone marrow cavities surrounded by thick osteoid seams with cuboidal osteoblasts. There is no significant difference in either of the indices between placebo- or TAK-778/PLGA-MC-treated skulls. Two months after the operation, the TAK-778/PLGA-MC pellets induce radiological osseous union across the defects[2]. Oral treatment of OVX rats with TAK-778 causes a more pronounced increase in bone mineral density (BMD) of the lumbar vertebrae compare to vehicle controls[3].
[Cell Assay]
Human bone marrow cells are used and cultured in α-MEM supplemented with 10% fetal bovine serum, 50 mg/mL gentamicin, 0.3 mg/mL fungizone, 100 nM Mdexamethasone, 5 mg/L ascorbic acid, and 7 mM bglycerophosphate. Subconfluent cells in primary culture are harvested after treatment with 1 mM EDTA and 0.25% trypsin and the first passage is subcultured in 24-well culture plates at a cell density of 2×104 cells/well in culture medium containing the same volume of TAK-778 (10 μM), Tamoxifen (10 μM), and TAK-778 (10 μM)+Tamoxifen (10 μM). Cells subcultured in medium supplemented with vehicle are used as a control. During the culture period, cells are incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% air, and the medium is changed every 3 or 4 days[1].
[Animal admin]
Eight-week-old female Wistar-Imamichi rats are used in this study. Forty Wistar-Imamichi rats are divided into sham-operated, vehicle, TAK-778, tamoxifen, and combination (TAK-778 and tamoxifen) treatment groups. Two weeks after ovariectomy, animals are orally administered TAK-778 [100 mg/kg body weight (BW), three times per week] and/or tamoxifen (200 mg/kg BW, three times per week) for 3 months. Rats orally administered vehicle and sham operated rats serve as controls. On 13 and 3 days before killing, tetracycline (30 mg/kg BW) or calcein (5 mg/kg BW) is injected subcutaneously, and lumbar vertebrae (L2-L5) are removed for bone analysis[3].
[References]
[Related Small Molecules]
Captisol
|
Cyclosporin A
|
H2DCFDA
|
0MPTP hydrochloride
|
GW4869
|
Etomoxir
|
TD139
|
Mitoquinone mesylate
|
GSK2795039
|
JC-1
|
BAPTA-AM
|
AP 20187
|
Setanaxib (GKT137831)
|
D-Luciferin
|
Crotaline
Chemical & Physical Properties
[ Molecular Formula ]:
C24H28NO7PS
[ Molecular Weight ]:
505.52
[ Storage condition ]:
2-8℃